A Phase 4 interventional study of dimethyl fumarate in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 19 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.
Sponsored by Biogen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 4, and was the 9th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2014.
This study's enrollment of 214 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 61 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 26th largest by enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2014, is one of 21 in phase 4, and was the 46th registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal-related events reported by participants with relapsing-remitting multiple sclerosis initiating therapy with BG00012 (dimethyl fumarate, DMF) in the clinical practice setting.
The secondary objectives of this study in this study population are as follows: to evaluate gastrointestinal-related events requiring symptomatic therapy and the role of those therapies over time; to evaluate gastrointestinal-related events that lead to a physician's decision to manage the events with BG00012 dose modification; and to evaluate gastrointestinal-related events that lead to BG00012 discontinuation after the use of symptomatic therapy.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.
Drug: dimethyl fumarate
capsules administered according to the prevailing product label
Also known as: BG00012, Tecfidera, DMF
Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal Symptom Scale (MOGISS)
The MOGISS is a questionnaire about the severity of overall gastrointestinal-related events, including specifically symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence for 24 hours before the AM dose. Participants who rated the intensity of symptoms reported on the MOGISS and included each symptomatic therapy used in the eDiary are presented.
Time frame: Up to Week 12
Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Acute Gastrointestinal Symptom Scale (MAGISS)
The MAGISS is a questionnaire in which participants reported overall acute gastrointestinal-related events, (especially symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) for each 10 hours after the AM and PM doses of study drug. Participants who rated the intensity of gastrointestinal-related events reported on MAGISS, included the duration of the gastrointestinal-related events and each symptomatic therapy used in the eDiary are presented.
Time frame: Up to Week 12
Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS
The MOGISS is a questionnaire about overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. MOGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.
Time frame: Up to Week 12
Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MAGISS
The MAGISS is a questionnaire about the overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) following drug administration (acute symptoms). MAGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.
Time frame: Up to Week 12
Duration of Gastrointestinal-Related Events in Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS
The percentage of days with GI events as reported on MOGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with \[GI\] events / # of days tolerability scale completed). The symptomatic therapy (ST) categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.
Time frame: Up to Week 12
Duration of Gastrointestinal-Related Events in Participants Who Utilize Symptomatic Therapy During the 12-Week Treatment Period, MAGISS
Percentage of days with GI events as reported on MAGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with \[GI\] events / # of days tolerability scale completed). The ST categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.
Time frame: Up to Week 12
Percentage of Participants Who First Took Symptomatic Therapy for Gastrointestinal-Related Events at Weeks 4, 8, and 12
The cumulative percentage of dimethyl fumarate-treated participants with relapsing-remitting multiple sclerosis who required symptomatic therapy up to Week 4, Week 8, and Week 12 were estimated using the Kaplan-Meier method.
Time frame: Week 4, Week 8, Week 12
Number of Participants Who Used Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category
Symptomatic therapies were classified into 10 main categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (includes Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon \& Iberogast, Iberogast \& Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (non-steroidal anti-inflammatory drug \[NSAID\]; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). Participants may have taken \> 1 symptomatic therapy but were counted only once for the 'All therapies' summary.
Time frame: Up to Week 12
Duration of Use of Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category
Symptomatic therapies were classified into 10 categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (eg, Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon \& Iberogast, Iberogast \& Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (NSAID; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in 'All therapies'.
Time frame: Up to Week 12
Percentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events
Dose reductions are defined as participants who take any dimethyl fumarate 120 mg or 0 mg since initiation of dimethyl fumarate 240 mg.
Time frame: Up to Week 12
Percentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events
Time frame: Up to Week 12
| Milestone | Dimethyl Fumarate |
|---|---|
| Started | 211 |
| Completed | 180 |
| Not completed | 31 |
| Withdrew: Other | 4 |
| Withdrew: Investigator decision | 1 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Consent withdrawn | 4 |
| Withdrew: Adverse event | 20 |
The MOGISS is a questionnaire about the severity of overall gastrointestinal-related events, including specifically symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence for 24 hours before the AM dose. Participants who rated the intensity of symptoms reported on the MOGISS and included each symptomatic therapy used in the eDiary are presented.
| Participants | Dimethyl Fumarate |
|---|---|
| Overall Treatment Period; n=211 | 82 |
| Weeks 1-4; n=211 | 71 |
| Weeks 5-8; n=186 | 33 |
| Weeks 9-12; n=178 | 22 |
The MAGISS is a questionnaire in which participants reported overall acute gastrointestinal-related events, (especially symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) for each 10 hours after the AM and PM doses of study drug. Participants who rated the intensity of gastrointestinal-related events reported on MAGISS, included the duration of the gastrointestinal-related events and each symptomatic therapy used in the eDiary are presented.
| Participants | Dimethyl Fumarate |
|---|---|
| Overall Treatment Period; n=211 | 83 |
| Weeks 1-4; n=211 | 72 |
| Weeks 5-8; n=189 | 34 |
| Weeks 9-12; n=180 | 26 |
The MOGISS is a questionnaire about overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. MOGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.
| units on a scale | Dimethyl Fumarate |
|---|---|
| Overall treatment period; n=84 | 5.94 ± 2.427 |
| Week 1-4; n=73 | 5.75 ± 2.554 |
| Week 5-8; n=38 | 3.53 ± 2.533 |
| Week 9-12; n=29 | 3.1 ± 2.568 |
The MAGISS is a questionnaire about the overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) following drug administration (acute symptoms). MAGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.
| units on a scale | Dimethyl Fumarate |
|---|---|
| Overall treatment period; n=84 | 5.93 ± 2.516 |
| Week 1-4; n=73 | 5.88 ± 2.614 |
| Week 5-8; n=39 | 3.31 ± 2.307 |
| Week 9-12; n=29 | 3.55 ± 2.772 |
The percentage of days with GI events as reported on MOGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with \[GI\] events / # of days tolerability scale completed). The symptomatic therapy (ST) categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.
| percentage of days | Dimethyl Fumarate |
|---|---|
| Overall treatment period; Any ST (n=84) | 38.13 ± 29.263 |
| Overall treatment period; ST1 (n=50) | 42.08 ± 27.495 |
| Overall treatment period; ST2 (n=26) | 36.98 ± 29.754 |
| Overall treatment period; ST3 (n=20) | 39.61 ± 29.197 |
| Overall treatment period; ST4 (n=16) | 48.15 ± 30.140 |
| Overall treatment period; ST5 (n=10) | 45.94 ± 27.147 |
| Overall treatment period; ST6 (n=8) | 44.33 ± 29.095 |
| Overall treatment period; ST7 (n=6) | 57.52 ± 21.998 |
| Overall treatment period; ST8 (n=5) | 52.71 ± 31.829 |
| Overall treatment period; ST9 (n=3) | 32.78 ± 26.995 |
| Overall treatment period; ST10 (n=2) | 9.20 ± 2.137 |
| Week 1-4; Any ST (n=73) | 49.58 ± 29.547 |
| Week 1-4; ST1 (n=44) | 53.92 ± 27.197 |
| Week 1-4; ST2 (n=23) | 49.53 ± 32.012 |
| Week 1-4; ST3 (n=18) | 55.31 ± 29.869 |
| Week 1-4; ST4 (n=13) | 56.63 ± 25.764 |
| Week 1-4; ST5 (n=9) | 44.42 ± 32.470 |
| Week 1-4; ST6 (n=6) | 48.48 ± 35.539 |
| Week 1-4; ST7 (n=6) | 69.78 ± 24.808 |
| Week 1-4; ST8 (n=5) | 66.43 ± 31.400 |
| Week 1-4; ST9 (n=3) | 41.41 ± 34.085 |
| Week 1-4; ST10 (n=0) | NA ± NA |
| Week 5-8; Any ST (n=38) | 41.55 ± 38.612 |
| Week 5-8; ST1 (n=23) | 44.04 ± 41.414 |
| Week 5-8; ST2 (n=3) | 41.67 ± 52.042 |
| Week 5-8; ST3 (n=8) | 37.45 ± 37.388 |
| Week 5-8; ST4 (n=3) | 69.14 ± 44.186 |
| Week 5-8; ST5 (n=3) | 63.75 ± 31.332 |
| Week 5-8; ST6 (n=3) | 70.42 ± 25.699 |
| Week 5-8; ST7 (n=1) | 35.71 ± NA |
| Week 5-8; ST8 (n=2) | 56.88 ± 40.032 |
| Week 5-8; ST9 (n=0) | NA ± NA |
| Week 5-8; ST10 (n=2) | 1.79 ± 2.525 |
| Week 9-12; Any ST (n=29) | 43.27 ± 42.322 |
| Week 9-12; ST1 (n=15) | 47.66 ± 43.191 |
| Week 9-12; ST2 (n=3) | 82.72 ± 29.937 |
| Week 9-12; ST3 (n=6) | 48.85 ± 50.931 |
| Week 9-12; ST4 (n=4) | 22.12 ± 20.834 |
| Week 9-12; ST5 (n=2) | 62.50 ± 53.033 |
| Week 9-12; ST6 (n=0) | NA ± NA |
| Week 9-12; ST7 (n=0) | NA ± NA |
| Week 9-12; ST8 (n=2) | 9.26 ± 13.095 |
| Week 9-12; ST9 (n=0) | NA ± NA |
| Week 9-12; ST10 (n=0) | NA ± NA |
The cumulative percentage of dimethyl fumarate-treated participants with relapsing-remitting multiple sclerosis who required symptomatic therapy up to Week 4, Week 8, and Week 12 were estimated using the Kaplan-Meier method.
| percentage of participants | Dimethyl Fumarate |
|---|---|
| Week 4 | 35.3 |
| Week 8 | 38.4 |
| Week 12 | 41.1 |
Symptomatic therapies were classified into 10 main categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (includes Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon \& Iberogast, Iberogast \& Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (non-steroidal anti-inflammatory drug \[NSAID\]; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). Participants may have taken \> 1 symptomatic therapy but were counted only once for the 'All therapies' summary.
| participants | Dimethyl Fumarate |
|---|---|
| Overall treatment period (OTP): All therapies | 84 |
| OTP: Anti-acid production | 50 |
| OTP: Anti-bloating/anti-constipation agent | 26 |
| OTP: Multi-target/herbal agents | 20 |
| OTP: Anti-diarrheal (anti-peristaltic) | 16 |
| OTP: Analgesic (NSAID) | 10 |
| OTP: Anti-emetic (central) | 8 |
| OTP: Anti-emetic (pro-kinetic) | 6 |
| OTP: Antacid | 5 |
| OTP: Other | 3 |
| OTP: Laxative (pro-kinetic) | 2 |
| Week 1-4: All therapies | 73 |
| Week 1-4: Anti-acid production | 44 |
| Week 1-4: Anti-bloating/anti-constipation agent | 23 |
| Week 1-4: Multi-target/herbal agents | 18 |
| Week 1-4: Anti-diarrheal (anti-peristaltic) | 13 |
| Week 1-4: Analgesic (NSAID) | 9 |
| Week 1-4: Anti-emetic (central) | 6 |
| Week 1-4: Anti-emetic (pro-kinetic) | 6 |
| Week 1-4: Antacid | 5 |
| Week 1-4: Other | 3 |
| Week 5-8: All therapies | 38 |
| Week 5-8: Anti-acid production | 23 |
| Week 5-8: Multi-target/herbal agents | 8 |
| Week 5-8: Analgesic (NSAID) | 3 |
| Week 5-8: Anti-bloating/anti-constipation agent | 3 |
| Week 5-8: Anti-diarrheal (anti-peristaltic) | 3 |
| Week 5-8: Anti-emetic (central) | 3 |
| Week 5-8: Antacid | 2 |
| Week 5-8: Laxative (pro-kinetic) | 2 |
| Week 5-8: Anti-emetic (pro-kinetic) | 1 |
| Week 9-12: All therapies | 29 |
| Week 9-12: Anti-acid production | 15 |
| Week 9-12: Multi-target/herbal agents | 6 |
| Week 9-12: Anti-diarrheal (anti-peristaltic) | 4 |
| Week 9-12: Anti-bloating.anti-constipation agent | 3 |
| Week 9-12: Analgesic (NSAID) | 2 |
| Week 9-12: Antacid | 2 |
Symptomatic therapies were classified into 10 categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (eg, Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon \& Iberogast, Iberogast \& Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (NSAID; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in 'All therapies'.
| days | Dimethyl Fumarate |
|---|---|
| OTP: All therapies; n=84 | 13.15 ± 19.21 |
| OTP: Anti-acid production; n=50 | 16.62 ± 22.21 |
| OTP: Anti-bloating/anti-constipation agent; n=26 | 2.42 ± 1.81 |
| OTP: Multi-target/herbal agents; n=20 | 9.40 ± 13.95 |
| OTP: Anti-diarrheal (anti-peristaltic); n=16 | 3.13 ± 2.53 |
| OTP: Analgesic (NSAID); n=10 | 3.10 ± 1.73 |
| OTP: Anti-emetic (central); n=8 | 3.25 ± 4.43 |
| OTP: Anti-emetic (pro-kinetic); n=6 | 1.83 ± 0.98 |
| OTP: Antacid; n=5 | 3.60 ± 4.22 |
| OTP: Other; n=3 | 1.67 ± 0.58 |
| OTP: Laxative (pro-kinetic); n=2 | 1.00 ± 0.00 |
| Week 1-4: All therapies; n=73 | 6.03 ± 6.12 |
| Week 1-4: Anti-acid production; n=44 | 7.07 ± 6.73 |
| Week 1-4: Anti-bloating/anti-constipation; n=23 | 2.30 ± 1.89 |
| Week 1-4: Multi-target/herbal agents; n=18 | 3.78 ± 3.06 |
| Week 1-4: Anti-diarrheal (anti-peristaltic); n=13 | 2.62 ± 1.45 |
| Week 1-4: Analgesic (NSAID); n=9 | 2.11 ± 0.93 |
| Week 1-4: Anti-emetic (central); n=6 | 3.17 ± 3.92 |
| Week 1-4: Anti-emetic (pro-kinetic); n=6 | 1.67 ± 0.82 |
| Week 1-4: Antacid; n=5 | 1.80 ± 1.30 |
| Week 1-4: Other; n=3 | 1.67 ± 0.58 |
| Week 5-8: All therapies; n=38 | 10.08 ± 10.56 |
| Week 5-8: Anti-acid production; n=23 | 13.00 ± 11.14 |
| Week 5-8: Multi-target/herbal agents; n=8 | 8.50 ± 10.45 |
| Week 5-8: Analgesic (NSAID); n=3 | 2.00 ± 1.00 |
| Week 5-8: Anti-bloating/anti-constipation; n=3 | 1.33 ± 0.58 |
| Week 5-8: Anti-diarrheal (anti-peristaltic); n=3 | 4.00 ± 3.61 |
| Week 5-8: Anti-emetic (central); n=3 | 2.33 ± 1.15 |
| Week 5-8: Antacid; n=2 | 2.50 ± 2.12 |
| Week 5-8: Laxative (pro-kinetic); n=2 | 1.00 ± 0.00 |
| Week 5-8: Anti-emetic (prokinetic); n=1 | 1.00 ± NA |
| Week 9-12: All therapies; n=29 | 9.72 ± 10.31 |
| Week 9-12: Anti-acid production; n=15 | 14.73 ± 10.91 |
| Week 9-12: Multi-target/herbal agents; n=6 | 8.67 ± 8.57 |
| Week 9-12: Anti-diarrheal (anti-peristaltic); n=4 | 1.00 ± 0.00 |
| Week 9-12: Anti-bloating/anti-constipation; n=3 | 2.00 ± 1.00 |
| Week 9-12: Analgesic (NSAID); n=2 | 3.00 ± 0.00 |
| Week 9-12: Antacid; n=2 | 2.00 ± 1.41 |
Dose reductions are defined as participants who take any dimethyl fumarate 120 mg or 0 mg since initiation of dimethyl fumarate 240 mg.
| percentage of participants | Dimethyl Fumarate |
|---|---|
| Percentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events | 34.6 |
| percentage of participants | Dimethyl Fumarate |
|---|---|
| Percentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events | 6.6 |
Percentage of days with GI events as reported on MAGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with \[GI\] events / # of days tolerability scale completed). The ST categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.
| percentage of days | Dimethyl Fumarate |
|---|---|
| Overall treatment period; Any ST (n=84) | 38.20 ± 30.516 |
| Overall treatment period; ST1 (n=50) | 41.29 ± 29.517 |
| Overall treatment period; ST2 (n=26) | 33.67 ± 27.310 |
| Overall treatment period; ST3 (n=20) | 39.28 ± 29.165 |
| Overall treatment period; ST4 (n=16) | 49.94 ± 33.291 |
| Overall treatment period; ST5 (n=10) | 45.65 ± 27.118 |
| Overall treatment period; ST6 (n=8) | 44.71 ± 30.374 |
| Overall treatment period; ST7 (n=6) | 55.32 ± 23.097 |
| Overall treatment period; ST8 (n=5) | 53.42 ± 31.443 |
| Overall treatment period; ST9 (n=3) | 36.92 ± 27.800 |
| Overall treatment period; ST10 (n=2) | 10.88 ± 1.924 |
| Week 1-4; Any ST (n=73) | 51.03 ± 30.360 |
| Week 1-4; ST1 (n=44) | 54.41 ± 29.608 |
| Week 1-4; ST2 (n=23) | 47.84 ± 30.764 |
| Week 1-4; ST3 (n=18) | 56.67 ± 30.711 |
| Week 1-4; ST4 (n=13) | 58.90 ± 27.111 |
| Week 1-4; ST5 (n=9) | 53.74 ± 32.304 |
| Week 1-4; ST6 (n=6) | 46.43 ± 33.221 |
| Week 1-4; ST7 (n=6) | 67.54 ± 25.296 |
| Week 1-4; ST8 (n=5) | 69.86 ± 28.919 |
| Week 1-4; ST9 (n=3) | 47.61 ± 47.61 |
| Week 1-4; ST10 (n=0) | NA ± NA |
| Week 5-8; Any ST (n=38) | 40.59 ± 37.836 |
| Week 5-8; ST1 (n=23) | 41.59 ± 41.442 |
| Week 5-8; ST2 (n=3) | 47.14 ± 45.781 |
| Week 5-8; ST3 (n=8) | 38.50 ± 35.493 |
| Week 5-8; ST4 (n=3) | 62.58 ± 45.775 |
| Week 5-8; ST5 (n=3) | 56.33 ± 33.011 |
| Week 5-8; ST6 (n=3) | 71.61 ± 24.587 |
| Week 5-8; ST7 (n=1) | 35.71 ± NA |
| Week 5-8; ST8 (n=2) | 62.24 ± 32.456 |
| Week 5-8; ST9 (n=0) | NA ± NA |
| Week 5-8; ST10 (n=2) | 10.00 ± 14.142 |
| Week 9-12; Any ST (n=29) | 41.28 ± 42.466 |
| Week 9-12; ST1 (n=15) | 44.24 ± 44.754 |
| Week 9-12; ST2 (n=3) | 76.19 ± 41.239 |
| Week 9-12; ST3 (n=6) | 51.99 ± 50.113 |
| Week 9-12; ST4 (n=4) | 15.48 ± 10.178 |
| Week 9-12; ST5 (n=2) | 63.16 ± 52.103 |
| Week 9-12; ST6 (n=0) | NA ± NA |
| Week 9-12; ST7 (n=0) | NA ± NA |
| Week 9-12; ST8 (n=2) | 13.11 ± 7.655 |
| Week 9-12; ST9 (n=0) | NA ± NA |
| Week 9-12; ST10 (n=0) | NA ± NA |
Collected over Serious adverse events: from signing of informed consent through last dose (up to 12 weeks (±5 days) plus 2 weeks (±5 days) follow up. Adverse events: from time of first dose of dimethyl fumarate through last dose (up to 12 weeks (±5 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dimethyl Fumarate | — | 5/211 (2.4%) | 129/211 (61.1%) |
| Event | Dimethyl Fumarate |
|---|---|
| Multiple sclerosis relapseNervous system disorders | 2/211 |
| HypersensitivityImmune system disorders | 1/211 |
| Alanine aminotransferase increrasedInvestigations | 1/211 |
| Aspartate aminotransferaseInvestigations | 1/211 |
| Gamma-glutamyltransferaseInvestigations | 1/211 |
| Alcohol abusePsychiatric disorders | 1/211 |
| Event | Dimethyl Fumarate |
|---|---|
| FlushingVascular disorders | 105/211 |
| NasopharyngitisInfections and infestations | 31/211 |
| HeadacheNervous system disorders | 14/211 |
| FatigueGeneral disorders | 12/211 |
| PruritisSkin and subcutaneous tissue disorders | 12/211 |
| Age, Continuous(years) | Dimethyl Fumarate |
|---|---|
| Mean | 40.09 ± 10.97 |
| Sex: Female, Male(Participants) | Dimethyl Fumarate |
|---|---|
| Female | 149 |
| Male | 62 |
The record gives a start of Jun 2014, a primary completion of Feb 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Multiple Sclerosis, Relapsing-Remitting →